QUOTE AND NEWS
Business Wire  Nov 12  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that David Arkowitz, Executive Vice President, Chief Financial Officer and Chief Business Officer will present an overview of the Company at the Lazard Capital Markets 6th Annual Healthcare
StreetInsider.com  Oct 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/AMAG+Pharma+%28AMAG%29+Posts+Q3+Loss+of+%241.29/5054334.html for the full story.
Business Wire  Oct 29  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular
Business Wire  Oct 21  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the third quarter ended September 30, 2009 before the U.S. financial markets open on October 29, 2009. The announcement will be
Market Intelligence Center  Oct 5  Comment 
AMAG Pharmaceuticals (AMAG) was downgraded today by analysts at Jefferies & Co. and the stock is now at $39.67, down $1.47 (-3.57%) on volume of 526,363 shares traded. The brokerage reduced the stock to Hold from Buy. Over the last 52 weeks the...
newratings.com  Oct 5  Comment 
Business Wire  Sep 10  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and Chief Executive Officer, will provide an update on the Company and answer questions at the Morgan Stanley Global Healthcare Unplugged Conference on
Market Intelligence Center  Sep 10  Comment 
Advanced Magnetics (AMAG) was downgraded today by analysts at Citigroup and the stock is now at $40.54, down $3.16 (-7.23%) on volume of 991,322 shares traded. The analysts downgraded the stock to Hold from Buy. Over the last 52 weeks the stock...
TheStreet.com  Sep 10  Comment 
Citi analyst cuts AMAG on slow Feraheme launch
  Sep 6  Comment 
Rockwell Medical (NASDAQ: RMTI ) has the potential for significant stock price gains by 2012 based on the enhanced earnings power of at least $4/share at that time for its lead clinical compound Soluble Ferric Pyrophosphate (SFP) with just a 20%...
Business Wire  Sep 4  Comment 
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its Board of Directors has adopted a Shareholder Rights Plan (“Rights Plan”) under which all shareholders of record as of September 17, 2009 will receive rights to purchase shares of
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
 
TOP CONTRIBUTORS
AMAG AT A GLANCE
 
 
 
 
 
 
 
 

Amag Pharmaceuticals Inc., formerly known as Advanced Magnetics Inc., develops and markets superparamagnetic iron oxide nanoparticles used in pharmaceutical products. The company is dedicated to the development and commercialization of its proprietary nanoparticle technology for use in therapeutic iron compounds to treat anemia, as well as imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company has two approved products, Feridex IV and GastroMARK, which are marketed primarily in the U.S. and Europe. Feridex IV is a liver contrast agent, and GastroMARK is an oral contrast agent used for delineating the bowel in MRI. The company has two primary product candidates, Ferumoxytol and Combidex. Ferumoxytol is in phase III multi-center clinical trials for use as an iron replacement therapeutic in chronic kidney disease patients, whether or not on dialysis. Combidex is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging (MRI) to aid in the differentiation of cancerous from normal lymph nodes.

Amag Pharmaceuticals was incorporated in Delaware in 1981 and is based in Cambridge, Massachusetts.




References

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki